+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Branded Generics Market - Global Forecast 2026-2032- Product Image
Branded Generics Market - Global Forecast 2026-2032- Product Image
Sale

Branded Generics Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5896414
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Branded Generics Market is projected to reach USD 405.14 Billion in 2026. It is expected to continue growing at a CAGR of 6.29%, reaching USD 585.24 Billion by 2032.

Branded generics are off-patent medicines sold under proprietary brand names, combining generic-drug cost advantages with brand-led trust, differentiated packaging, physician familiarity, and patient adherence support. In many markets, branded generic drugs occupy a critical position between innovator brands and unbranded generics, particularly where prescribing decisions are influenced by clinical confidence, pharmacy availability, perceived quality, and continuity of supply.

Demand is supported by patent expirations, aging populations, rising chronic disease prevalence, and payer pressure to reduce pharmaceutical expenditure. Verified public health sources, including the FDA and WHO, consistently show the central role of generic medicines in improving access and reducing medicine costs, while branded generics remain especially relevant in emerging markets where brand reputation, regulatory compliance, and quality assurance are strong purchase drivers.

Transformative Shifts in the Branded Generics Landscape

The branded generics landscape is shifting from volume-led expansion to evidence-backed, quality-focused competition. Governments are tightening price controls, expanding reference pricing, promoting generic substitution, and using centralized procurement to lower drug costs, forcing manufacturers to defend value through reliability, therapeutic breadth, and differentiated service models.

At the same time, supply chain resilience has become a board-level priority. Manufacturers are diversifying active pharmaceutical ingredient sourcing, investing in serialization and track-and-trace systems, and aligning with stricter good manufacturing practice expectations as regulators increase scrutiny of product quality, bioequivalence, pharmacovigilance, and medicine shortages.

Cumulative Impact of Artificial Intelligence in Branded Generics

Artificial intelligence is accelerating branded generics decision-making across portfolio selection, demand forecasting, manufacturing quality, regulatory intelligence, and safety monitoring. AI-enabled analytics can identify attractive loss-of-exclusivity opportunities, predict demand fluctuations, support inventory planning, and improve pharmacovigilance signal detection from structured and unstructured real-world data.

The impact is cumulative because each use case strengthens the next: better forecasting supports supply reliability, stronger quality analytics reduce batch deviations, and real-world evidence improves product positioning and post-market monitoring. Leaders must pair AI adoption with validated models, data lineage, cybersecurity controls, privacy compliance such as HIPAA or GDPR where applicable, and GxP-ready governance for regulated pharmaceutical operations.

Key Regional Insights for Branded Generics

Asia-Pacific remains a major growth engine for branded generics, supported by India and China manufacturing scale, Japan’s pro-generic reimbursement policies, and expanding healthcare coverage across Southeast Asia. The region benefits from large patient populations, increasing chronic disease treatment needs, and policy efforts to improve access to affordable medicines, while regulators continue strengthening quality, bioequivalence, and pharmacovigilance expectations.

North America is shaped by FDA abbreviated approval pathways, high generic prescription utilization, payer formularies, state-level substitution rules, and competitive pharmacy benefit management dynamics. Latin America continues to expand through public-sector access programs and regulatory modernization in markets such as Brazil and Mexico, where medicine affordability and pharmacy-based access remain important drivers. Europe is defined by mature generic substitution policies, national reimbursement controls, and EMA-aligned quality expectations, with governments closely monitoring availability and medicine shortages. The Middle East is investing in localization, tender modernization, and medicine-security strategies, while Africa’s opportunity is tied to essential medicine access, reduced import dependence, stronger national regulatory systems, and regional harmonization initiatives supported by public health authorities.

Key Group Insights Across Strategic Branded Generics Markets

ASEAN markets are becoming more attractive as regulatory convergence, health coverage expansion, and private pharmacy networks improve access to branded generics across diverse income and healthcare settings. The GCC is advancing localization, tender efficiency, and medicine-security strategies, creating opportunities for compliant manufacturers with regional partnerships, resilient supply chains, and consistent regulatory documentation.

The European Union emphasizes affordability, pharmacovigilance, quality assurance, and supply continuity through coordinated regulation and national pricing systems. BRICS economies combine large patient pools, rising noncommunicable disease burdens, and manufacturing depth, while also applying stronger regulatory oversight and procurement discipline. G7 markets reward high compliance, dependable supply, and evidence-supported differentiation despite sustained price pressure from payers and health technology assessment practices. NATO members increasingly view pharmaceutical supply resilience, essential medicine availability, and cross-border preparedness as part of broader health-security planning.

Key Country Insights for Priority Branded Generics Markets

The United States leads in generic utilization, supported by FDA regulation, payer formularies, and a deep retail pharmacy network, while Canada emphasizes public and private reimbursement discipline, provincial formulary management, and cost-effective access. Mexico and Brazil are expanding branded generic demand through large populations, chronic disease burdens, growing pharmacy channels, and evolving regulatory capacity focused on safety, quality, and bioequivalence.

The United Kingdom, Germany, France, Italy, and Spain maintain mature access systems where reimbursement, prescribing rules, reference pricing, and pharmacy substitution shape competition for branded generics. Russia remains driven by localization policy, public procurement, and essential medicine demand. China and India are pivotal for scale, active pharmaceutical ingredient supply, formulation manufacturing, and domestic access priorities, while China’s volume-based procurement and India’s quality-focused regulatory strengthening influence competitive behavior. Japan, Australia, and South Korea prioritize quality, aging-population demand, regulated reimbursement pathways, and stringent post-market expectations, making compliance and reliable supply central to branded generic success.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize branded generic portfolios around high-burden chronic diseases, proven bioequivalence, dependable supply, and markets with favorable loss-of-exclusivity timing. Commercial strategy should combine physician education, pharmacy engagement, patient adherence tools, and localized branding that communicates quality, access, and continuity without overstating clinical differentiation.

Executives should strengthen dual sourcing, regional manufacturing options, regulatory intelligence, shortage-risk monitoring, and real-world evidence generation. AI investments should start with validated use cases in demand planning, pharmacovigilance, regulatory surveillance, and quality assurance, supported by transparent governance, auditable data, cybersecurity controls, and clear accountability for regulatory compliance.

Research Methodology

This executive summary is built on a structured research methodology combining secondary research, regulatory review, policy assessment, market triangulation, and expert interpretation. Publicly verifiable sources include regulator guidance, national medicine agencies, WHO essential medicine frameworks, FDA and EMA resources, OECD health indicators, and published pharmaceutical policy and access literature from recognized public and institutional sources.

Findings are assessed through product, geography, regulatory, payer, prescribing, pharmacy, and supply chain lenses. Insights are validated by comparing policy direction, medicine utilization trends, patent-expiry dynamics, manufacturing capacity, quality requirements, pharmacovigilance expectations, and reimbursement behavior to identify durable branded generics opportunities rather than short-term market noise.

Conclusion

Branded generics remain central to global pharmaceutical access because they balance affordability, therapeutic familiarity, and brand-based confidence. Their relevance is increasing as health systems seek cost containment while patients, pharmacists, and prescribers continue to value dependable quality, availability, and continuity of treatment.

The next phase of branded generics competition will favor organizations that combine regulatory excellence, resilient supply chains, evidence-based commercialization, localized access strategies, and responsible AI adoption. Winners will not compete on price alone; they will build trusted, compliant, and regionally adaptive branded generic platforms that support sustainable medicine access.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Branded Generics Market, by Dosage Form
7.1. Introduction
7.2. Injections
7.2.1. Intramuscular
7.2.2. Intravenous
7.2.3. Subcutaneous
7.3. Liquids
7.3.1. Suspensions
7.3.2. Syrups
7.4. Tablets & Capsules
7.4.1. Extended Release
7.4.2. Immediate Release
7.5. Topicals
7.5.1. Creams
7.5.2. Gels
7.5.3. Ointments
8. Branded Generics Market, by Therapeutic Area
8.1. Introduction
8.2. Anti-Infectives
8.2.1. Antibiotics
8.2.2. Antifungals
8.2.3. Antivirals
8.3. Cardiovascular
8.3.1. Anti-Dyslipidemics
8.3.2. Anti-Hypertensives
8.4. Central Nervous System
8.4.1. Anti-Depressants
8.4.2. Anti-Epileptics
8.4.3. Anti-Psychotics
8.5. Gastrointestinal
8.5.1. Antacids
8.5.2. Laxatives
8.6. Pain Management
8.6.1. Non-Opioid Analgesics
8.6.2. Opioids
9. Branded Generics Market, by Application
9.1. Introduction
9.2. Animal Health
9.2.1. Companion Animals
9.2.1.1. Cats
9.2.1.2. Dogs
9.2.2. Livestock
9.3. Human Health
10. Branded Generics Market, by Distribution Channel
10.1. Introduction
10.2. Online
10.3. Offline
11. Branded Generics Market, by Region
11.1. Asia-Pacific
11.2. Europe
11.3. North America
11.4. Latin America
11.5. Africa
11.6. Middle East
12. Branded Generics Market, by Group
12.1. NATO
12.2. G7
12.3. BRICS
12.4. European Union
12.5. ASEAN
12.6. GCC
13. Branded Generics Market, by Country
13.1. China
13.2. United States
13.3. Japan
13.4. India
13.5. Germany
13.6. United Kingdom
13.7. Australia
13.8. France
13.9. South Korea
13.10. Italy
13.11. Canada
13.12. Russia
13.13. Brazil
13.14. Mexico
13.15. Spain
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. Alembic Pharmaceuticals Limited
15.3. Alkem Laboratories Limited
15.4. Apotex Inc.
15.5. Aspen Pharmacare Holdings Limited
15.6. Aurobindo Pharma Limited
15.7. Bausch Health Companies Inc.
15.8. Biocon Limited
15.9. Cipla Limited
15.10. Dr. Reddy’s Laboratories Ltd.
15.11. Emcure Pharmaceuticals Limited
15.12. Endo International plc
15.13. Fresenius Kabi AG
15.14. Glenmark Pharmaceuticals Limited
15.15. Hikma Pharmaceuticals PLC
15.16. Jubilant Pharmova Limited
15.17. Krka, d. d., Novo mesto
15.18. Lupin Limited
15.19. Mankind Pharma Limited
15.20. Natco Pharma Limited
15.21. Pfizer Inc.
15.22. Sandoz Group AG
15.23. Sanofi S.A.
15.24. STADA Arzneimittel AG
15.25. Sun Pharmaceutical Industries Ltd.
15.26. Teva Pharmaceutical Industries Ltd.
15.27. Torrent Pharmaceuticals Limited
15.28. Viatris Inc.
15.29. Wockhardt Limited
15.30. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL BRANDED GENERICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BRANDED GENERICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BRANDED GENERICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BRANDED GENERICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BRANDED GENERICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INJECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INJECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INJECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL LIQUIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL LIQUIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL LIQUIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SUSPENSIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SUSPENSIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL SYRUPS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL SYRUPS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL SYRUPS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL TABLETS & CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL TABLETS & CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL TABLETS & CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL EXTENDED RELEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL EXTENDED RELEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL EXTENDED RELEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TOPICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TOPICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL TOPICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CREAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL GELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL GELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL OINTMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL OINTMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL OINTMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ANTI-DYSLIPIDEMICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ANTI-DYSLIPIDEMICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ANTI-DYSLIPIDEMICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ANTI-HYPERTENSIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ANTI-HYPERTENSIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ANTI-HYPERTENSIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ANTI-DEPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ANTI-DEPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ANTI-DEPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ANTI-EPILEPTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ANTI-EPILEPTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ANTI-EPILEPTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ANTI-PSYCHOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ANTI-PSYCHOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ANTI-PSYCHOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL GASTROINTESTINAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL GASTROINTESTINAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL GASTROINTESTINAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ANTACIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL LAXATIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL LAXATIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL LAXATIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL NON-OPIOID ANALGESICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL NON-OPIOID ANALGESICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL NON-OPIOID ANALGESICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL ANIMAL HEALTH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL ANIMAL HEALTH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL COMPANION ANIMALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL COMPANION ANIMALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL COMPANION ANIMALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL CATS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL CATS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL CATS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL DOGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL DOGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL DOGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL LIVESTOCK MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL LIVESTOCK MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL LIVESTOCK MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL HUMAN HEALTH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL HUMAN HEALTH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HUMAN HEALTH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 141. EUROPE BRANDED GENERICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. EUROPE BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 143. EUROPE BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 144. EUROPE BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 145. EUROPE BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 146. EUROPE BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 147. EUROPE BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 148. EUROPE BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 149. EUROPE BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 150. EUROPE BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 151. EUROPE BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 152. EUROPE BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 153. EUROPE BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 154. EUROPE BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 155. EUROPE BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 156. EUROPE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 169. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 170. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 171. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 172. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 182. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 183. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 184. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 185. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 186. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 187. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 188. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. AFRICA BRANDED GENERICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. AFRICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 191. AFRICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 192. AFRICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 193. AFRICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 194. AFRICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 195. AFRICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 196. AFRICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 197. AFRICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 198. AFRICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 199. AFRICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 200. AFRICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 201. AFRICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 202. AFRICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 203. AFRICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 204. AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 212. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 213. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 214. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 215. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 216. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 217. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 218. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 219. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 220. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. GLOBAL BRANDED GENERICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 222. NATO BRANDED GENERICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 223. NATO BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 224. NATO BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 225. NATO BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 226. NATO BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 227. NATO BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 228. NATO BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 229. NATO BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 230. NATO BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 231. NATO BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 232. NATO BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 233. NATO BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 234. NATO BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 235. NATO BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 236. NATO BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 237. NATO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 238. G7 BRANDED GENERICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 239. G7 BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 240. G7 BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 241. G7 BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 242. G7 BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 243. G7 BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 244. G7 BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 245. G7 BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 246. G7 BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 247. G7 BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 248. G7 BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 249. G7 BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 250. G7 BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 251. G7 BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 252. G7 BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 253. G7 BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. BRICS BRANDED GENERICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 255. BRICS BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 256. BRICS BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 257. BRICS BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 258. BRICS BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 259. BRICS BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 260. BRICS BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 261. BRICS BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 262. BRICS BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 263. BRICS BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 264. BRICS BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 265. BRICS BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 266. BRICS BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 267. BRICS BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 268. BRICS BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 269. BRICS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 283. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 284. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 285. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 286. ASEAN BRANDED GENERICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 287. ASEAN BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 288. ASEAN BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 289. ASEAN BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 290. ASEAN BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 291. ASEAN BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 292. ASEAN BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 293. ASEAN BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 294. ASEAN BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 295. ASEAN BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 296. ASEAN BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 297. ASEAN BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 298. ASEAN BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 299. ASEAN BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 300. ASEAN BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 301. ASEAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 302. GCC BRANDED GENERICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 303. GCC BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 304. GCC BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 305. GCC BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 306. GCC BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 307. GCC BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 308. GCC BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 309. GCC BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 310. GCC BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 311. GCC BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 312. GCC BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 313. GCC BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 314. GCC BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 315. GCC BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 316. GCC BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 317. GCC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 318. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 319. CHINA BRANDED GENERICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. CHINA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 321. CHINA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 322. CHINA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 323. CHINA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 324. CHINA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 325. CHINA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 326. CHINA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 327. CHINA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 328. CHINA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 329. CHINA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 330. CHINA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 331. CHINA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 332. CHINA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 333. CHINA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 334. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 335. UNITED STATES BRANDED GENERICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 336. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 337. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 338. UNITED STATES BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 339. UNITED STATES BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 340. UNITED STATES BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 341. UNITED STATES BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 342. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 343. UNITED STATES BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 344. UNITED STATES BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 345. UNITED STATES BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 346. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 347. UNITED STATES BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 348. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 349. UNITED STATES BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 350. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 351. JAPAN BRANDED GENERICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 352. JAPAN BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 353. JAPAN BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 354. JAPAN BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 355. JAPAN BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 356. JAPAN BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 357. JAPAN BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 358. JAPAN BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 359. JAPAN BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 360. JAPAN BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 361. JAPAN BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 362. JAPAN BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 363. JAPAN BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 364. JAPAN BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2017-2032 (USD MILLION)
TABLE 365. JAPAN BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2017-2032 (USD MILLION)
TABLE 366. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 367. INDIA BRANDED GENERICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 368. INDIA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 369. INDIA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2017-2032 (USD MILLION)
TABLE 370. INDIA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2017-2032 (USD MILLION)
TABLE 371. INDIA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2017-2032 (USD MILLION)
TABLE 372. INDIA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 373. INDIA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 374. INDIA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2017-2032 (USD MILLION)
TABLE 375. INDIA BRANDED GENERICS MARKET SIZE, BY CA

Companies Mentioned

  • Abbott Laboratories
  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Limited
  • Apotex Inc.
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Emcure Pharmaceuticals Limited
  • Endo International plc
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Limited
  • Krka, d. d., Novo mesto
  • Lupin Limited
  • Mankind Pharma Limited
  • Natco Pharma Limited
  • Pfizer Inc.
  • Sandoz Group AG
  • Sanofi S.A.
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • Viatris Inc.
  • Wockhardt Limited
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 405.14 Billion
Forecasted Market Value ( USD ) by 2032 $ 585.24 Billion
Compound Annual Growth Rate6.2%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Generic Injectables Market - Global Forecast 2026-2032 - Product Image

Generic Injectables Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Specialty Generics Market - Global Forecast 2026-2032 - Product Image

Specialty Generics Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Branded Generics - Global Strategic Business Report - Product Image

Branded Generics - Global Strategic Business Report

  • Report
  • 354 Pages
  • Global
From
Generic Pharmaceuticals Contract Manufacturing - Global Strategic Business Report - Product Image

Generic Pharmaceuticals Contract Manufacturing - Global Strategic Business Report

  • Report
  • 494 Pages
  • Global
From
Branded Generics Market Size, Share & Trends Analysis Report by Drug Class, Application, Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2026-2033 - Product Image

Branded Generics Market Size, Share & Trends Analysis Report by Drug Class, Application, Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From

About the Branded Generics Market

Branded generics are generic drugs that are marketed under a brand name. They are typically manufactured by a generic drug company, but are sold under a brand name owned by a pharmaceutical company. Branded generics are typically sold at a higher price than generic drugs, but are still much cheaper than the original brand-name drug. They are often used to increase the market share of a generic drug company, as well as to increase the visibility of a generic drug in the marketplace. Branded generics are becoming increasingly popular in the pharmaceutical industry, as they offer a cost-effective alternative to brand-name drugs. They are also used to increase the market share of generic drug companies, as well as to increase the visibility of generic drugs in the marketplace. Some companies in the branded generics market include Teva Pharmaceuticals, Mylan, Sandoz, and Dr. Reddy's Laboratories. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.